Pembrolizumab and Olaparib for People With Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy identifier:
NCT04666740 (


Study Contact Information:

For additional information, please contact:

Wungki Park, MD by phone: 646 888-4543 or by email.           

Eileen O'Reilly, MD 646-888-4182

About the Study

This is a study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy. The goal of this study is to look at whether combining the immunotherapy drug, pembrolizumab and the PARP inhibitor, olaparib is a more effective treatment for this cancer than taking olaparib alone.

Type of Study

The study is an open-label, non-randomized study with three treatment groups. 

Study participants whose cancer is stable or responded responded to first-line or second-line platinum therapy will be divided into three groups:

What the Study Entails

Patients in all three study groups will receive the following treatments:

Therapy will continue as long as the cancer does not get worse and patients are tolerating treatment. 

Study Site

New York, NY: Memorial Sloan Kettering Cancer Center
Contact: Wungki Park, MD by phone at 646-888-4543 or by email.      

This Study is Open To:

Men or women age 18 years or older can participate if they:  

This Study is Not Open To:

Patients will be excluded if they have:  


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.